市場調査レポート

商品コード

1801138

喘息治療の市場規模、シェア、動向、予測：薬剤クラス別、製品タイプ別、治療タイプ別、投与経路別、地域別、2025～2033年

Asthma Therapeutics Market Size, Share, Trends and Forecast by Drug Class, Product Type, Treatment Type, Route of Administration, and Region, 2025-2033

出版日: 2025年08月01日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 445,531円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペースト、印刷はできません。

PDF & Excel (5 User License)

USD 3,999 594,091円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストはできませんが、印刷は5部まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 742,651円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピー&ペーストは可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.56円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

喘息治療の世界市場規模は2024年に188億3,000万米ドルとなりました。今後、IMARC Groupは、2033年には221億米ドルに達し、2025～2033年にかけて1.8%のCAGRを示すと予測しています。現在市場を独占しているのは北米ので、2024年の市場シェアは50.0%を超えます。北米市場の成長の原動力は、先進的ヘルスケアインフラ、喘息有病率の高さ、革新的な治療オプション、研究開発への旺盛な投資です。同地域が大きなシェアを占めているのは、先進的な生物製剤や併用療法が広く使用されていることに加え、新製品の承認に有利な規制の枠組みが整備されているためです。

大気汚染、アレルゲン、気候変動などの環境の影響や遺伝的要因に関連して、喘息の罹患率が世界的に増加していることから、より先進的治療に対する需要が高まっています。さらに、生物製剤や併用薬などの新しい治療法の出現は、喘息治療に変革をもたらしつつあります。これらの治療は炎症や気管支収縮を標的とし、特に標準的な治療に反応しない中等度から重度の患者に対して、より高い有効性と患者に合わせた選択肢を記載しています。さらに、特に重症の喘息に対する先進的生物製剤と併用治療の利用が増加しており、喘息治療市場の展望は良好です。モノクローナル抗体を含むこれらの治療法は、患者の治療成績を大幅に向上させる的確な選択肢を記載しています。さらに、政府機関や非政府組織（NGO）は、喘息の早期発見と効果的な管理の重要性に関する啓発活動を精力的に行っており、患者が迅速な治療を受け、配合された治療法に従うよう動機づけています。

米国は、新規治療法の有効性を実証する臨床検査の成功に牽引され、市場において重要なセグメントとなっています。臨床検査の良好な結果は、特に重篤な増悪の軽減や長期管理の改善など、アンメット・メディカル・ニーズに対応する画期的な治療法の承認につながることが多いです。このようなイノベーションは、治療効果における新たな基準を設定するものです。2024年、AstraZenecaはBATURA第III相検査の良好な結果を報告し、同社のレスキュー吸入薬AIRSUPRA（R）（アルブテロール/ブデソニド）が、間欠性または軽度の持続性喘息患者における重症喘息発作の可能性を大幅に低下させることを示しました。この検査は、効果が顕著であったため、早期に中止されました。AIRSUPRAは、米国で初めて承認された喘息治療のための抗炎症レスキュー治療です。

喘息治療市場動向

喘息の有病率の増加

特に先進国や都市部における世界の喘息罹患率の上昇が、喘息治療市場の需要を牽引する重要な要因となっています。世界保健機関（WHO）は、2019年には2億6,200万人が喘息に罹患し、4億5,500万人が死亡したと発表しています。大気汚染、アレルゲン、気候変動などの環境要因は、現代の生活習慣と相まって、特に高所得国や急速に都市化する地域で喘息の有病率を強めています。疾病負担の増加により、軽症から重症の喘息患者を治療する、従来型吸入薬から先進的生物製剤や標的療法に至るまで、さまざまな治療に対するニーズが生まれています。さらに、特定の個人を対象とした治療アプローチである個別化医療が重視されるようになり、創薬における技術革新の大きな原動力となっています。喘息患者の入院を減らし、生活の質を向上させるための継続的な努力により、研究への継続的な投資と世界のヘルスケア・アクセスの改善に支えられ、市場はさらに成長すると予想されます。

治療選択肢の進歩

革新的な喘息治療、特に生物製剤や標的治療の開発により、治療選択肢は大幅に進歩し、患者の転帰も改善しつつあります。これらの治療は、肺の機能を高めながら気道の炎症を抑え、重症度の異なる患者の喘息管理をより効果的なものにしています。さらに、有効性の向上や増悪率の減少を通じて、医療従事者や患者による生物製剤の利点に対する認識が高まった結果、その採用が増加しています。喘息の有病率の高さは、こうした治療の必要性を浮き彫りにしています。例えば、米国疾病予防管理センターによる2021年の報告によると、5歳から11歳までの小児の7.5％が喘息を経験しています。現在進行中の研究イニシアチブは、画期的な薬剤の規制認可と相まって競合環境に影響を与え、進歩を促進し、喘息患者の満たされない要求に世界的に対処しています。

意識の高まりと早期診断

喘息の管理と早期発見に関する意識の高まりが、喘息治療市場を牽引しています。情報や先進的診断機器にアクセスしやすくなったことで認知度が向上し、患者はタイムリーな治療を求めるようになったため、適切な治療に対する需要が高まっています。ヘルスケア機関や政府は、喘息のコントロール対策に関する教育を強化する教育プログラムを開発し、定期的なチェックと与えられた治療法のフォローアップをさらに強化しています。デジタルヘルスプラットフォームやスマート吸入器による技術の進歩は、患者が積極的に疾病管理を行うことを可能にしています。新製品の発売により、市場ではアンメット・メディカル・ニーズへの対応が続いています。例えば、2023年9月、欧州の連合（EU）は、高用量吸入コルチコステロイド薬によるコントロールが不十分な12歳以上の重症喘息治療として、AstraZenecaのテズスパイア（テゼペルマブ）を承認しました。こうした開発は、喘息治療市場の成長を支える技術革新と認知度の役割を強調しています。

北米
- 米国
- カナダ
アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ

第11章 SWOT分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- AstraZeneca PLC
- Abbott Laboratories
- Amgen Inc.
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Merck Sharp & Dohme Corp.
- Novartis International AG
- Sunovion Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.

図表

List of Figures

Figure 1: Global: Asthma Therapeutics Market: Major Drivers and Challenges
Figure 2: Global: Asthma Therapeutics Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Asthma Therapeutics Market: Breakup by Drug Class (in %), 2024
Figure 4: Global: Asthma Therapeutics Market: Breakup by Product Type (in %), 2024
Figure 5: Global: Asthma Therapeutics Market: Breakup by Treatment Type (in %), 2024
Figure 6: Global: Asthma Therapeutics Market: Breakup by Route of Administration (in %), 2024
Figure 7: Global: Asthma Therapeutics Market: Breakup by Region (in %), 2024
Figure 8: Global: Asthma Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 9: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Asthma Therapeutics (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Asthma Therapeutics (Bronchodilators) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Asthma Therapeutics (Bronchodilators) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Asthma Therapeutics (Combination Therapies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Asthma Therapeutics (Combination Therapies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Asthma Therapeutics (Inhalers) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Asthma Therapeutics (Inhalers) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Asthma Therapeutics (Nebulizers) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Asthma Therapeutics (Nebulizers) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Asthma Therapeutics (Quick-Relief Medications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Asthma Therapeutics (Quick-Relief Medications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Asthma Therapeutics (Long-Term Asthma Control Medications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Asthma Therapeutics (Inhalation) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Asthma Therapeutics (Inhalation) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Asthma Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Asthma Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Asthma Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Asthma Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: North America: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: North America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: United States: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: United States: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Canada: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Canada: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Asia Pacific: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Asia Pacific: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: China: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: China: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: Japan: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: Japan: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: India: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: India: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: South Korea: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: South Korea: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Australia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Australia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Indonesia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Indonesia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: Europe: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: Europe: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: Germany: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: Germany: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: France: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: France: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: United Kingdom: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: United Kingdom: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: Italy: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: Italy: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Spain: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Spain: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: Russia: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: Russia: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Latin America: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Latin America: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Brazil: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Brazil: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Mexico: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Mexico: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Others: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Others: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Middle East and Africa: Asthma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Middle East and Africa: Asthma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: Global: Asthma Therapeutics Industry: SWOT Analysis
Figure 78: Global: Asthma Therapeutics Industry: Value Chain Analysis
Figure 79: Global: Asthma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Asthma Therapeutics Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Asthma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
Table 3: Global: Asthma Therapeutics Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
Table 4: Global: Asthma Therapeutics Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
Table 5: Global: Asthma Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
Table 6: Global: Asthma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Asthma Therapeutics Market Structure
Table 8: Global: Asthma Therapeutics Market: Key Players

Product Code: SR112025A2338

The global asthma therapeutics market size was valued at USD 18.83 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 22.1 Billion by 2033, exhibiting a CAGR of 1.8% from 2025-2033. North America currently dominates the market, holding a market share of over 50.0% in 2024. The growth of the North American market is driven by advanced healthcare infrastructure, high asthma prevalence, innovative treatment options, and strong investment in research and development. The region holds a significant asthma therapeutics market share because of the extensive use of advanced biologics and combination therapies, coupled with supportive regulatory frameworks that favor new product approvals.

The increasing incidence of asthma globally, linked to environmental influences like air pollution, allergens, and climate shifts, along with genetic factors, is creating a demand for more sophisticated treatments. Additionally, the emergence of new treatments, such as biologics and combination medications, is transforming asthma care. These therapies target inflammation and bronchoconstriction, providing enhanced effectiveness and customized options for moderate to severe instances, particularly for individuals who do not respond to standard treatments. Furthermore, the increasing utilization of sophisticated biologics and combination treatments, especially for severe asthma situations, is offering a favorable asthma therapeutics market outlook. These therapies, including monoclonal antibodies, provide precise options that greatly enhance patient results. In addition, government bodies and non-governmental organizations (NGOs) are vigorously running awareness initiatives regarding the significance of early detection and effective management of asthma, motivating patients to pursue prompt treatment and follow prescribed therapies.

The United States is a crucial segment in the market, driven by the success of clinical trials demonstrating the efficacy of novel treatments. Positive trial results often lead to the approval of groundbreaking therapies that address unmet medical needs, particularly in reducing severe exacerbations and improving long-term management. These innovations set new standards in treatment efficacy. In 2024, AstraZeneca reported favorable outcomes from the BATURA Phase III trial, indicating that its rescue inhaler AIRSUPRA(R) (albuterol/budesonide) considerably lowered the likelihood of severe asthma attacks in individuals with intermittent or mild persistent asthma. The trial was halted prematurely because of remarkable effectiveness. AIRSUPRA is the inaugural anti-inflammatory rescue treatment authorized in the US for managing asthma.

Asthma Therapeutics Market Trends:

Increasing Prevalence of Asthma

The rising incidence of asthma globally, particularly in developed and urbanized regions, is a significant factor driving the asthma therapeutics market demand. The World Health Organization (WHO) states that in 2019, 262 million individuals suffered from asthma, leading to 455,000 fatalities. Environmental factors such as air pollution, allergens, and climate changes, coupled with modern lifestyle habits, have intensified the prevalence of asthma, especially in high-income nations and rapidly urbanizing regions. Increased disease burden creates a need for a variety of treatments ranging from conventional inhalers to advanced biologics and targeted therapies treating both mild and severe asthma patients. Moreover, the emphasis on personalized medicine, treatment approaches aimed at specific individuals, has acted as a major driver of innovations in drug discovery. With continuous endeavors to reduce hospitalization and improve the quality of life for asthma patients, the market is only expected to grow further, supported by continued investments in research and improved healthcare access worldwide.

Advancements in Treatment Options

Development of innovative asthma therapeutics, particularly biologics and targeted therapies, is advancing treatment options significantly and improving patient outcomes. The solutions are reducing airway inflammation while enhancing lung function, making the management of asthma in patients with different levels of severity more effective. Additionally, the increase in awareness about the benefits of biologics by health care providers and patients through increased efficacy and decreased exacerbation rates has resulted in its increased adoption. The high prevalence of asthma highlights the necessity for these therapies. For instance, as per the 2021 report by the US Centers for Disease Control and Prevention, 7.5% of children between the ages of 5 and 11 experienced asthma. Ongoing research initiatives, coupled with regulatory authorizations for groundbreaking medications, are influencing a competitive environment, fostering progress, and addressing the unfulfilled requirements of asthma sufferers globally.

Increasing Awareness and Early Diagnosis

Rising awareness about the management of asthma and the early detection of asthma have driven the asthma therapeutics market. As the awareness has improved with the accessibility of information and advanced diagnostic equipment, the patient has been seeking timely treatment and therefore a high demand for proper treatments. Healthcare organizations and the government develop educational programs that increase education on asthma control measures, making it even more a periodic check and following up with given therapies. The advancement in technology through digital health platforms and smart inhalers is enabling patients to be proactive in disease management. With the launch of new products, unmet medical needs continue to get addressed in the market. For example, in September 2023, the European Union approved AstraZeneca's Tezspire (tezepelumab) for the treatment of severe asthma in patients aged 12 and older who are inadequately controlled with high-dose inhaled corticosteroids. These developments underline the role of innovation and awareness in supporting the asthma therapeutics market growth.

Asthma Therapeutics Industry Segmentation:

Analysis by Drug Class:

Anti-Inflammatory Drugs
Bronchodilators
Combination Therapies

Combination therapies lead the market because of their effectiveness in tackling various aspects of asthma management in one treatment. These treatments often merge inhaled corticosteroids (ICS) with long-acting beta-agonists (LABAs), providing anti-inflammatory advantages and prolonged bronchodilation. Their dual-action mechanism offers both instant relief from airway constriction and diminishes chronic inflammation, rendering them very effective for moderate to severe asthma instances. The ease of having one therapy improves patient adherence and streamlines treatment plans, especially for individuals with ongoing symptoms. Improvements in formulation technology have facilitated the creation of more focused and long-lasting combination treatments, enhancing clinical results and reducing side effects. Pharmaceutical companies are focusing on launching new products, like triple-combination therapies, to enhance treatment choices. Regulatory approvals and favorable clinical data have strengthened healthcare providers' confidence in these therapies, reinforcing their position as the favored option for thorough asthma management.

Analysis by Product Type:

Inhalers
- Dry Powder Inhalers
- Metered Dose Inhalers
- Soft Mist Inhalers
Nebulizers
- Pneumatic Nebulizers
- Ultrasonic Nebulizers
- Mesh Nebulizers

Inhalers (dry powder inhalers, metered-dose inhalers, and soft mist inhalers), hold the biggest asthma therapeutics market share because of their extensive application and efficacy in directly administering medications to the lungs. Metered-dose inhalers are favored for their small size and accurate medication delivery, whereas dry powder inhalers provide user-friendliness without requiring propellants. Soft mist inhalers, featuring a fine mist and reliable dosing, serve patients who need a more gentle delivery method. The use of inhalers is motivated by their capacity for quick relief and sustained control, rendering them essential in the management of asthma. Innovations in technology, including smart inhalers equipped with digital tracking features, have improved treatment adherence and patient results. Furthermore, continuous advancements in formulation and device design are enhancing usability and effectiveness, making inhalers the preferred option for healthcare professionals and patients in asthma management.

Analysis by Treatment Type:

Quick-Relief Medications
Long-Term Asthma Control Medications

Long-term asthma control medications dominate the market due to their efficacy in controlling chronic asthma and decreasing both the occurrence and intensity of flare-ups. These drugs, such as inhaled corticosteroids, long-acting beta-agonists (LABAs), leukotriene modifiers, and biologics, aim to tackle the root inflammation and ensure stable lung performance over time. Their capacity to deliver reliable symptom control and enhance patients' quality of life establishes them as the foundation of asthma management approaches. Heightened awareness regarding the significance of consistent and preventive care has led to their common utilization. Improvements in biological treatments aimed at severe asthma cases, like monoclonal antibodies, have enhanced the segment's attractiveness by providing personalized and targeted solutions for patients not responding to conventional therapies. Pharmaceutical firms are actively funding research and development to launch novel combination medications and delivery systems, improving both effectiveness and patient compliance. Regulatory endorsements and broadened uses for biologics reinforce the sector's dominance in asthma treatments.

Analysis by Route of Administration:

Inhalation
Oral
Parenteral

Inhalers represent the largest segment, accounting 47.0% of the market share in 2024. Inhalation is the largest segment because it effectively administers medications straight to the lungs, providing quick symptom relief and improved treatment results. Inhaled treatments, such as corticosteroids, bronchodilators, and combination medications, are commonly favored for their targeted effects, which reduce systemic side effects relative to alternative methods of administration. The presence of different inhalation devices, including metered-dose inhalers, dry powder inhalers, and nebulizers, has enhanced patient compliance by providing choices suited to personal requirements. Advancements in technology, like smart inhalers equipped with digital tracking features, have increased the adoption of inhalation therapies by facilitating better asthma control through real-time monitoring of how medications are used. Regulatory approvals for novel formulations and the introduction of biosimilars in the inhalation sector have strengthened its dominance. Continual efforts by pharmaceutical companies to enhance the efficacy and convenience of inhaled medications strengthen their position as the primary choice for asthma treatment.

Regional Analysis:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

In 2024, North America held the largest market share, totaling 50.0%. North America dominates the market due to its strong healthcare infrastructure, significant research efforts, and widespread use of advanced medical technologies. The area gains from a significant presence of major pharmaceutical firms and solid regulatory structures that ease the approval and marketing of groundbreaking asthma therapies. Supportive healthcare policies and substantial government investment in respiratory disease research also enhance market expansion. Furthermore, the increasing incidence of asthma, influenced by environmental and genetic factors, has heightened the need for efficient treatment options. Furthermore, partnerships between academic institutions and industry stakeholders are driving the creation of innovative biologics and personalized medicine strategies, reinforcing North America's dominance in the asthma therapeutics sector. In 2024, Jasper Therapeutics announced that they have administered the first dose to a patient in the Phase 1b/2a ETESIAN clinical trial for briquilimab, a monoclonal antibody targeting c-Kit, designed for allergic asthma. The research will enroll 30 individuals from seven locations in Canada to evaluate the drug's efficacy, emphasizing mast cell reduction and respiratory response. The initial results are expected by the end of 2025.

Key Regional Takeaways:

United States Asthma Therapeutics Market Analysis

In North America, the United States represented 90.00% of the overall market share. In fact, the US asthma therapeutics market is growing with increased prevalence among people across different demographic categories. As highlighted by the CDC in 2020, almost 25 million people were estimated to be living with asthma in the U.S., further confirming the large number of affected populations. Also, adult women suffer disproportionately from asthma more than men do, indicating a need for individualized treatments for this demographic segment. More to this, children form a susceptible group, as per the Asthma and Allergy Foundation of America, where there are 5 million children asthmatic in the United States.

The high prevalence of asthma in adults and children is driving the demand for effective management strategies, including advanced inhalers, biologics, and combination therapies. Increased awareness about the importance of asthma control and early diagnosis has also encouraged more patients to seek medical intervention. These factors, coupled with ongoing innovation in asthma therapeutics, contribute to the expanding market in the United States, addressing the diverse needs of asthmatic patients across age groups.

Europe Asthma Therapeutics Market Analysis

The rising prevalence of asthma is fueling the asthma therapeutics market in Europe. Over 30 million adults and children are suffering from asthma in Europe, as has been reported by the European Lung Foundation, which clearly underlines the burden this chronic respiratory condition imposes. Women suffer more from asthma than men. This means there is a need for specific therapies that address the needs of this gender. Children, on the other hand, still form a susceptible population. The chronic illness, asthma, stands out as the most common condition among children in the region.

With the importance of early diagnosis and effective management surfacing awareness on advanced treatments such as biologics, combination therapies, and new inhalers, the overall need for this increase is coming out. Controlling asthma as proposed by national healthcare initiatives in Europe coupled with guidelines reinforces controlling asthma. Overall, along with the evolution in therapeutic options that are developing at a continued rate, asthma therapeutics demand will continue growing for all different groups of ages that suffer from it.

Asia Pacific Asthma Therapeutics Market Analysis

The Asia Pacific asthma therapeutics market is expanding fast, due to the increased incidence of asthma within the region. In China, asthma rates increased from 0.69% in 1984 to 5.30% in 2021, and it is estimated that they will rise up to 9.76% by 2050, according to BMC Public Health. The sharp increase indicates a great demand for the management of asthma in one of the region's largest populations. India also has a significant asthma burden. According to the NIH, 34.3 million cases of asthma have been reported in India, accounting for 13.09% of the global disease burden.

With prevalence continuously on the rise, asthma is a strongly developing market, in terms of need for advance therapy, in form of biologics and combination therapies. It is supplemented with next generation inhalers also. Greater emphasis towards early stage diagnosis and subsequent treatment has ensured their adoption, not to speak of government sponsored health care provisions and an up rising middle class looking forward to enhance access to care. All such factors together placed Asia Pacific region at the highest.

Latin America Asthma Therapeutics Market Analysis

The Latin America asthma therapeutics market is currently witnessing healthy growth due to a high and continuously rising prevalence of asthma in the region. Data published by industry reports in 2023 indicates that the overall prevalence of asthma in Latin America is about 17%, and the rates go up to as high as 30% in countries like Costa Rica. Thus, this area reflects a major unmet need for asthma management solutions appropriately addressed to the heterogeneous populations of the region.

With increased awareness of asthma as a chronic condition and its impact on quality of life, the demand for advanced therapeutics, such as inhalers, biologics, and combination therapies, has been increasing. Improved healthcare infrastructure and access to medical facilities in many Latin American countries further support the adoption of these therapies. The importance of early diagnosis and preventive care by governments and healthcare providers are significant factors that can mitigate asthma. Together, these aspects make the asthma therapeutic market in Latin America continue to grow.

Middle East and Africa Asthma Therapeutics Market Analysis

The asthma therapeutics market in the Middle East and Africa (MEA) is experiencing significant growth because of the high incidence of asthma and severe asthma in many nations throughout the region. According to industry reports, severe asthma rates are significantly high in African nations, with Kenya and Uganda showing 27% and Ethiopia at 19.9%. These statistics have created a significant burden of asthma-related health issues in the area, raising the need for efficient asthma management strategies.

Greater awareness of asthma as a chronic disease, coupled with better access to healthcare facilities, is driving adoption of advanced therapeutic options, such as inhalers, biologics, and targeted therapies. In addition, the increased interest in early diagnosis and personalized treatment plans, especially in urbanized regions, has helped manage asthma better. Such factors, coupled with the upgrading of healthcare infrastructure and government policies, are supporting the growth of the asthma therapeutics market in the Middle East and Africa.

Competitive Landscape:

Major market participants are concentrating on innovation, strategic alliances, and geographic growth to strengthen their market presence. They are making significant investments in research and development to launch advanced biologics and combination therapies that enhance efficacy and patient adherence. Businesses are also utilizing digital health technologies, like smart inhalers and mobile apps, to better monitor and manage asthma symptoms. Regulatory authorizations for new formulations and biosimilars are being sought to enhance product portfolios. Collaborative alliances with academic institutions and biotech firms are aiding in the discovery of new therapeutic approaches. In 2024, Teva Pharmaceuticals announced a clinical collaboration with Abingworth, securing as much as $150M in funding to advance TEV-248, a late-stage asthma rescue inhaler that combines ICS/SABA for adult and pediatric patients. Launch Therapeutics will carry out clinical trials, while Teva will focus on production and marketing. This aligns with Teva's "Pivot to Growth" strategy, emphasizing the pipeline's expansion.

The report provides a comprehensive analysis of the competitive landscape in the asthma therapeutics market with detailed profiles of all major companies, including:

AstraZeneca PLC
Abbott Laboratories
Amgen Inc.
Biogen Inc.
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Merck Sharp & Dohme Corp.
Novartis International AG
Sunovion Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1.How big is the asthma therapeutics market?
2.What is the future outlook of asthma therapeutics market?
3.What are the key factors driving the asthma therapeutics market?
4.Which region accounts for the largest asthma therapeutics market share?
5.Which are the leading companies in the global asthma therapeutics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Asthma Therapeutics Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Class

6.1 Anti-Inflammatory Drugs
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Bronchodilators
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Combination Therapies
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Product Type

7.1 Inhalers
- 7.1.1 Market Trends
- 7.1.2 Major Types
  - 7.1.2.1 Dry Powder Inhalers
  - 7.1.2.2 Metered Dose Inhalers
  - 7.1.2.3 Soft Mist Inhalers
- 7.1.3 Market Forecast
7.2 Nebulizers
- 7.2.1 Market Trends
- 7.2.2 Major Types
  - 7.2.2.1 Pneumatic Nebulizers
  - 7.2.2.2 Ultrasonic Nebulizers
  - 7.2.2.3 Mesh Nebulizers
- 7.2.3 Market Forecast

8 Market Breakup by Treatment Type

8.1 Quick-Relief Medications
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Long-Term Asthma Control Medications
- 8.2.1 Market Trends
- 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

9.1 Inhalation
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Oral
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Parenteral
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 AstraZeneca PLC
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Abbott Laboratories
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Amgen Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Biogen Inc.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Boehringer Ingelheim International GmbH
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
- 15.3.6 F. Hoffmann-La Roche Ltd.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 SWOT Analysis
- 15.3.7 GlaxoSmithKline Plc
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Merck Sharp & Dohme Corp.
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Novartis International AG
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Sunovion Pharmaceuticals Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 SWOT Analysis
- 15.3.11 Teva Pharmaceutical Industries Ltd.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis

喘息治療の市場規模、シェア、動向、予測：薬剤クラス別、製品タイプ別、治療タイプ別、投与経路別、地域別、2025～2033年

Asthma Therapeutics Market Size, Share, Trends and Forecast by Drug Class, Product Type, Treatment Type, Route of Administration, and Region, 2025-2033

喘息治療市場動向

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界の喘息治療市場

第6章 市場内訳：薬剤クラス別

第7章 市場内訳：製品タイプ別

第8章 市場内訳：治療タイプ別

第9章 市場内訳：投与経路別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢